Natalia Fadeeva
A5005548803- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Barrier Structure and Function Studies
- HER2/EGFR in Cancer Research
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- CNS Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Elasticity and Material Modeling
- Economic and Financial Impacts of Cancer
Chelyabinsk Regional Clinical Oncology Center
2016-2025
Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with goal preferentially activating expanding effector CD8
LBA4001 Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ adenocarcinoma. IMAB362 chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells activation immune effector mechanisms. has demonstrated single-agent activity was safe tolerable in patients (pts) with pretreated cancer. Methods: Pts advanced/recurrent were centrally evaluated for CLDN18.2 expression IHC (validated CLAUDETECT18.2...
Aim. To evaluate the efficacy and safety profile of pembrolizumab biosimilar, Pembroria, in patients with advanced lung cancer routine clinical practice. Materials methods. The eligible for therapy based on standard indications without contraindications participated multicenter, multicohort, post-marketing, prospective, non-interventional study. primary endpoint was best objective response rate (ORR) assessed within six months treatment initiation. This report presents interim analysis...
Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce incidence duration neutropenia, febrile neutropenia (FN) infections associated with FN in patients lymphoproliferative diseases receiving myelosuppressive therapy.
 Materials methods. The paper presents results a multicenter retrospective-and-prospective observational post-marketing study cytotoxic therapy. Initially, was defined as...
LBA4001 The full, final text of this abstract will be available at abstracts.asco.org 7:30 AM (EDT) on Sunday, June 5, 2016, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
5536 Background: Here we present the final results of single-arm phase II CAESURA (NCT03912402) study prolgolimab (anti-PD-1 antibody) with platinum doublet and bevacizumab in subjects advanced cervical cancer (CC). Methods: 58 patients (pts) metastatic or recurrent/persistent CC measurable disease received (3 mg/kg) Q3W together paclitaxel, drug (cis- carboplatin) for 6 cycles then therapy until progression toxicity. Objective response rate (ORR) was assessed by central radiology review per...
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination PD-1 and CTLA-4 inhibitors a new standard care for patients with metastatic melanoma (MM). A significant limitation widespread use ipilimumab nivolumab routine clinical practice is high risk severe immune-mediated adverse events. Prolgolimab nurulimab are fixed doses original monoclonal antibodies (manufactured by JSC "BIOCAD," Russia) to receptor (prolgolimab) (nurulimab) (3:1...
e13035 Background: EMPOWER trial demonstrated the benefit of eribulin administrated post CD4/6i in patients (pts) with HR+ HER2-negative (HR+HER2-) metastatic breast cancer (MBC). There are several important limitations to this trial: > 60% pts were stage IV at time treatment initiation, used late lines (2L only 30% pts) and follow-up data immature. Current study aimed provide additional on real-world effectiveness safety monotherapy setting. Methods: Observation standard regimen enrolled...
Aim. To assess effectiveness and safety of Extimia BIOCAD (INN: empegfilgrastim) used to decrease the rate duration neutropenia, febrile neutropenia infections that manifest in patients with lymphoproliferative diseases who receive myelosuppressive therapy.
 Materials methods. The paper presents results second interim analysis multicenter retrospective-and-prospective observational post-marketing study cytotoxic therapy. stage describes patient characteristics, therapy 221...
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. approval studies MONALEESA-2 7 demonstrated the efficacy safety ribociclib aromatase as first-line post- premenopausal patients. In Phase lllb CompLEEment-1 study, same regimen was evaluated an extended patient population terms both efficacy. article presents analysis data from subgroup...
Prolgolimab is the first Russian PD-1 inhibitor approved for first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was in two weight-based regimens 1 mg/kg Q2W 3 Q3W, but because re-evaluation dosing paradigm, studying a fixed-dose regimen considered perspective.
9549 Background: MIRACULUM (NCT03269565) is a multicenter open-label parallel-arm phase II study investigating the antitumor activity of BCD-100, an IgG1 anti-PD-1 monoclonal antibody with Fc silencing “LALA” mutation, in patients advanced melanoma. Interim analysis at 6-months presented. Methods: Patients (pts) unresectable or metastatic melanoma, without autoimmune disease, and no prior anti-CTLA-4 therapy were eligible. Pts received BCD-100 1 mg/kg Q2W (arm 1) 3 Q3W 2) until disease...
3607 Background: Curaxin CBL0137 is a novel compound with broad anticancer activity in animal models. The drug non-genotoxic DNA intercalator that interferes histone/DNA binding causing decondensation of chromatin tumor cells, functional inactivation histone chaperone FACT, activation p53 and IFN responses, inhibition pro-cancer transcriptional factors, MYC, NF-kB, HSF1, HIF1a. Methods: study enrolled adults advanced chemorefractory solid tumors, ECOG PS ≤2, adequate organ function. primary...
<h3>Background</h3> Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the receptor-1 (PD-1) B7.1 receptors restore an anti-tumor immune response. has additional benefit of functional Fc domain capable inducing antibody-dependent cellular cytotoxicity complement-dependent against tumor cells. Study CK-301–101 global, multicenter, multicohort trial enrolling patients (pts) select...
The Advisory Board was held on December 24, 2021. molecular genetic research lead specialists and national oncologists discussed issues of diagnosis NTRK gene translocations in patients with non-small cell lung cancer (NSCLC), as well current opportunities for the treatment NSCLC caused by fusions. experts reaffirmed necessity to identify timely fusions, correct disease, including use modern diagnostic methods fusion (NGS is most sensitive specific method) determines success patient...